Ravidasvir plus sofosbuvir

Drug Profile

Ravidasvir plus sofosbuvir

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation
  • Class Benzimidazoles; Carbamates; Naphthalenes; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatitis C

Most Recent Events

  • 21 Dec 2016 Chemical structure information added
  • 01 Sep 2016 Phase-II/III clinical trials in Hepatitis C (Combination therapy) in Malaysia (PO) (NCT02961426)
  • 13 Apr 2016 Drugs for Neglected Diseases initiative and Pharco pharmaceuticals agree to co-develop ravidasvir/sofosbuvir in Malaysia and Thailand for Hepatitis C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top